Dr. Maria Soloveychik is the co-founder and CEO of SyntheX, a therapeutics company focused on accelerating drug discovery using synthetic biology. The company’s core technologies, ToRPPIDO and ToRNeDO, rely on genetic engineering and evolutionary selection to synthesize and identify compounds that disrupt protein-protein interactions or lead to selective target degradation. SyntheX was founded in 2016 and is located in San Francisco. Maria has obtained her PhD from the Department of Molecular Genetics at the University of Toronto, where she discovered novel pathways linking metabolism and epigenetic signaling. Maria was previously a research scientist at a structural genomics consortium at the University Health Network in Toronto, where her work led to the determination of numerous structures and identification of several drug candidates.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related